My company Kazia Therapeutics was until recently known as Novogen. Being established 23 years ago, the company has made many changes in recent months. The company is an oncology drug company and has recently started clinical trials on drugs for the treatment of cervical cancer and brain cancer throughout hospitals in Australia and the United States. The company is based in Sydney, Australia and has also recently made major changes to its personnel and organizational structure. Novogen becomes Kazia Therapeutics.
Kazia Therapeutics are the exclusive licensee for the development and trial of the drug GDC-0084 which was developed by Genentech Inc. (California). This drug is being trialed for the treatment of the aggressive form of brain cancer Glioblastoma Multiforme. Genentech completed the Phase I trials and now this has been licenced to Kazia Therapeutics for further trials, in consultation with neuro-oncologists from the United States. GDC-0084 Phase II
Cantrixil is another drug that Kazia Therapeutics will be trialling. This drug has been researched by Yale University and there is strong evidence that the drug was successfully active against two types of cancer cells. Cantrixil Phase I
I feel that I am going to have quite a few challenges understanding the intricacies of this company.
Mandy's blog 
One thought on “Kazia Therapeutics”